Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingnaojing injection
- Development stage
- Phase 4
- Lead developer
- Tasly Pharmaceutical
- Administration
- Intravenous
01
Overview
Xingnaojing injection (XNJ) is an approved traditional Chinese medicine (TCM) injection derived from the classical Angong Niuhuang pill formulation. It is composed of four primary active herbal ingredients: Moschus (musk), Borneolum syntheticum (synthetic borneol), Curcuma aromatica (radix curcumae), and Gardenia jasminoides (fructus gardenia). Xingnaojing is approved by the National Medical Products Administration (NMPA) of China as a neuroprotective agent and is indicated for the treatment of apoplectic coma, hemiplegia, acute ischemic stroke, and intracerebral hemorrhage. Its pharmacological mechanisms include scavenging free radicals, reducing cerebral edema and hypoxia, increasing brain cell metabolic activity, and modulating the PI3K/Akt/eNOS and SIRT1 signaling pathways to confer neuroprotection and anti-inflammatory effects.
- Other names
- XNJXNJIXingnaojingXingnaojing Zhusheye醒脑静注射液
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)PGK1 (Phosphoglycerate kinase 1)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)NOS3 (eNOS)
Beyond the preview
Go deeper on Xingnaojing injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xingnaojing injection.